Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMXYDMP)

Drug Name
LM10 Drug Info
Synonyms
1316695-35-8; (E)-3-(2-(1H-TETRAZOL-5-YL)VINYL)-6-FLUORO-1H-INDOLE; CHEMBL1812545; LM-10; 6-fluoro-3-[(E)-2-(1H-1,2,3,4-tetrazol-5-yl)ethenyl]-1H-indole; 6-Fluoro-3-[(1E)-2-(2H-tetrazol-5-yl)ethenyl]-1H-indole; 1H-Indole, 6-fluoro-3-[(1E)-2-(2H-tetrazol-5-yl)ethenyl]-; LM 10; GTPL9016; SCHEMBL16820602; SCHEMBL16820603; BDBM311862; CS-D0342; BDBM50350248; MFCD26097257; s8368; US10155972, Compound LM10; ZINC72108665; AKOS024464444; CCG-266788; AS-30527; Q27081058
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Preclinical [1]
Cross-matching ID
PubChem CID
135743630
TTD Drug ID
DMXYDMP

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Download the Complete Related Drug List
Drug(s) Targeting Tryptophan 2,3-dioxygenase (TDO)
Drug Name Drug ID Indication ICD 11 Highest Status REF
DN1406131 DMQFX8R Solid tumour/cancer 2A00-2F9Z Phase 1 [3]
HTI-1090 DMI4TEC Solid tumour/cancer 2A00-2F9Z Phase 1 [4]
2,3-diamino-benzo[b]thiophene derivative 4 DMEDFNC N. A. N. A. Patented [5]
PMID27172114-Compound-30 DMBWLSA N. A. N. A. Patented [5]
2,3-diamino-benzo[b]thiophene derivative 2 DMDYXKT N. A. N. A. Patented [5]
2,3-diamino-benzo[b]thiophene derivative 8 DM5O8K0 N. A. N. A. Patented [5]
2,3-diamino-benzo[b]thiophene derivative 7 DMQVMNJ N. A. N. A. Patented [5]
2,3-diamino-benzo[b]thiophene derivative 6 DMINE6V N. A. N. A. Patented [5]
2,3-diamino-benzo[b]thiophene derivative 5 DM05WXD N. A. N. A. Patented [5]
2,3-diamino-benzo[b]thiophene derivative 1 DMD2KRW N. A. N. A. Patented [5]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Tryptophan 2,3-dioxygenase (TDO) TTXNCBV T23O_HUMAN Inhibitor [2]

References

1 Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond. Nat Rev Drug Discov. 2019 May;18(5):379-401.
2 The autoimmune response elicited by mouse hepatitis virus (MHV-A59) infection is modulated by liver tryptophan-2,3-dioxygenase (TDO). Immunol Lett. 2020 Jan;217:25-30.
3 ClinicalTrials.gov (NCT03641794) Indoleamine 2,3-Dioxygenase (IDO) Inhibitor in Healthy Volunteers. U.S. National Institutes of Health.
4 Discovery of cyanopyridine scaffold as novel indoleamine-2,3-dioxygenase 1 (IDO1) inhibitors through virtual screening and preliminary hit optimisation. J Enzyme Inhib Med Chem. 2019 Dec;34(1):250-263.
5 Inhibitors of the kynurenine pathway as neurotherapeutics: a patent review (2012-2015).Expert Opin Ther Pat. 2016 Jul;26(7):815-32.